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Abstract 
 
Raleigh Elizabeth Malik 
 
THE ROLE OF DNA METHYLATION IN REGULATING  
LHX3 GENE EXPRESSION 
 
 LIM homeodomain 3 (LHX3) is an important regulator of pituitary and nervous 
system development. To date, twelve LHX3 gene mutations have been identified in 
patients with combined pituitary hormone deficiency disease (CPHD). Understanding the 
molecular mechanisms governing LHX3/Lhx3 gene regulation will provide critical 
insights into organ development pathways and associated diseases. DNA methylation has 
been implicated in gene regulation in multiple physiological systems. This dissertation 
examines the role of DNA methylation in regulating the murine Lhx3 gene. To determine 
if demethylation of the Lhx3 gene promoter would induce its expression, murine pre-
somatotrope pituitary cells that do not normally express Lhx3 (Pit-1/0 cells) were treated 
with the demethylating reagent, 5-Aza-2’-deoxycytidine. This treatment lead to activation 
of the Lhx3 gene and thus suggested that methylation contributes to Lhx3 gene regulation. 
Proteins that modify chromatin, such as histone deacetylases (HDACs) have also been 
shown to affect DNA methylation patterns and subsequent gene activation. Pit-1/0 
pituitary cells treated with a combination of the demethylating reagent and the HDAC 
inhibitor, Trichostatin A led to activation of the Lhx3 gene, suggesting crosstalk between 
DNA methylation and histone modification processes. To assess DNA methylation 
levels, treated and untreated Pit-1/0 genomic DNA were subjected to bisulfite conversion 
and sequencing. Treated Pit-1/0 cells had decreased methylation compared to untreated 
iv 
 
cells. Chromatin immunoprecipitation assays demonstrated interactions between the 
methyl-binding protein, MeCP2 and the Lhx3 promoter regions in the Pit-1/0 cell line. 
Overall, the study demonstrates that DNA methylation patterns of the Lhx3 gene are 
associated with its expression status.  
 
 
     Simon J. Rhodes, Ph.D.– Chair 
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INTRODUCTION 
1. The Anterior Pituitary Gland 
 The anterior pituitary gland regulates biological processes such as metabolism, 
growth, lactation, reproduction and stress. It controls these physiological and 
developmental events by producing hormones from five different hormone-secreting cell 
types—corticotropes, gonadotropes, thyrotropes, somatotropes and lactotropes. The 
corticotropes produce adrenocorticotropic hormone (ACTH) to regulate the stress 
response. ACTH is formed from the proteolytic cleavage of a precursor protein, 
proopiomelanocortin (POMC) (Stevens and White, 2010). Gonadotropes produce 
follicle-stimulating hormone (FSH) and luteinizing hormone (LH) to regulate 
reproduction, while thyrotropes produce thyroid-stimulating hormone (TSH) to regulate 
metabolism. FSH, LH and TSH are heterodimeric proteins composed of a common 
subunit, alpha-glycoprotein (αGSU) and a specific beta subunit (FSHβ, LHβ and TSHβ) 
(reviewed by (Savage et al., 2003; Zhu et al., 2007)). Somatotropes produce growth 
hormone (GH) to regulate growth. In humans, there is a cluster of five GH-related genes 
in which the most 5′ gene (hGH-N or GH1) is transcribed exclusively in somatotropes 
and lactosomatotropes of the anterior pituitary, which produce the pituitary GH protein 
(Savage et al., 2003; Baumann, 2009). Lactotropes produce prolactin (PRL) to regulate 
lactation and the human prolactin locus consists of a single gene driven by two 
promoters—a pituitary-specific promoter and an alternative promoter which drives 
expression in non-pituitary tissues (Featherstone et al., 2012). 
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1.1 Pituitary organogenesis 
 The pituitary relays signals between the hypothalamus and peripheral target 
organs (Zhu et al., 2007). The pituitary, located in the sella turcica of the sphenoid bone 
at the base of the brain, is composed of two distinct parts that are derived from two 
separate embryological sources (Savage et al., 2003; Kelberman et al., 2009). The 
adenohypophysis, comprising the anterior and intermediate lobes, arises from the oral 
ectoderm-derived Rathke’s pouch, while the neurohypophysis, also known as the 
posterior lobe, arises from the neural-derived infundibulum of the diencephalon. 
Inductive signaling between the diencephalon and Rathke’s pouch initiates a transcription 
factor cascade leading to the development of a mature anterior pituitary, which contains 
the five distinct hormone-secreting cell types (Figure 1). In this process, the diencephalon 
signaling factors, including the key factors bone morphogenetic protein (BMP) 4 and 
fibroblast growth factor (FGF) 8 induce the expression of the LIN11, ISL1, MEC3 
(LIM)-homeodomain 3 (LHX3) and the LIM-homeodomain 4 (LHX4) transcription 
factors that are essential for the development of a rudimentary Rathke’s pouch and 
subsequent pituitary development (Hunter and Rhodes, 2005; Alatzoglou et al., 2009). 
1.2 Pituitary transcription factors 
1.2.1 PIT-1 
 Pituitary-specific transcription factor-1 (PIT-1, also known as POU1F1) plays a 
critical role in somatotrope, lactotrope and thyrotrope cell development. It regulates 
genes such as Gh, Prl, Tshβ, growth hormone-releasing hormone (Ghrh) receptor and 
thyroid hormone receptor beta type 2 and its own gene through autoregulation (Andersen 
and Rosenfeld, 1994; Rhodes et al., 1996). The vital role of the PIT-1 in pituitary 
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development is exemplified in the Snell (dw) and Jackson (dwj) mouse models, which 
show thyrotrope, somatotrope and lactotrope cell deficiencies (Li et al., 1990). The Snell 
mouse dw phenotype occurs as a result of a Pit-1 gene mutation (Li et al., 1990; Fang et 
al., 2011). The mutation alters a conserved amino acid in the DNA-binding POU 
homeodomain of the transcription factor, ultimately preventing PIT-1 from binding key 
regulatory regions of anterior pituitary target genes (Li et al., 1990). The other mouse 
model, known as the Jackson dwarf mouse, carries an inactivating Pit-1 gene 
rearrangement (Li et al., 1990). The resulting dwj phenotype is similar to the Snell 
phenotype showing deficiencies in GH, TSH and PRL and to human diseases featuring 
PIT-1 gene mutations, suggesting that PIT-1 is a critical regulator of human pituitary 
gene functions (Li et al., 1990; Pfaffle and Klammt, 2011). 
The regulation of the Pit-1gene and PIT-1 structure 
 The Pit-1/POU1F1 gene is well characterized in rodents and humans and its gene 
expression is restricted to the caudomedial region of the pituitary gland (Zhu et al., 2007). 
In rodents, the Pit-1 proximal promoter is a 300 bp region surrounding the transcription 
start site. It contains a TATA box, two cyclic AMP response elements (CREs) in the rat 
or one CRE in the mouse and two autoregulatory PIT-1 binding sites. The positive PIT-1 
autoregulatory site is upstream, while a negative site is downstream and position 
dependent (McCormick et al., 1990; de la Hoya et al., 1998). The rodent Pit-1 gene also 
has a distal enhancer containing additional PIT-1 autoregulatory binding sites, a vitamin 
D receptor element, a PIT-1 retinoic acid response element and a putative Prophet of Pit-
1 (PROP-1) binding site (Rhodes et al., 1993; DiMattia et al., 1997; de la Hoya et al., 
1998). 
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 The human PIT-1 minimal promoter spans nucleotides -102 to +15 relative to the 
Pit-1 transcription start site, and contains an autoregulatory PIT-1 binding element as 
well as additional cis elements that confer high basal transcriptional activity (Delhase et 
al., 1996). Unlike the rodent promoter sequence, the human proximal and distal 
promoters do not contain a CRE (de la Hoya et al., 1998). Additionally, the distal 
promoter region contains autoregulatory binding sites, but does not show interaction with 
the minimal promoter (Delhase et al., 1996). Expression of the human PIT-1 gene is also 
down regulated by the OCT-1 and AP-1 transcription factors (Delhase et al., 1996). 
 PIT-1 belongs to the POU homeodomain family. The protein is comprised of an 
amino (N-) terminal activation domain and two domains responsible for high affinity 
DNA binding: a POU-specific domain that is located closer to the N-terminus and a 
carboxyl (C-)terminal POU homeodomain. The PIT-1 protein recognizes AT-rich 
nucleotide sequences in the pituitary-expressed GH, PRL and TSHβ promoters (Kerr et 
al., 2008) 
Pit-1 lineage cell lines  
 Recently, Sizova and colleagues characterized three new mouse cell lines 
representing PIT-1-associated cell lineages (Sizova et al., 2010). Mouse Pit-1 or GH gene 
regulatory sequences (Pit-Tag or GH-Tag) were used to guide expression of the SV40 
large T-antigen oncoprotein (Tag) to the developing pituitaries of transgenic mice. Three 
cell lines were derived from tumors: Pit-1/0, Pit-1/Triple and Pit-1/Prl and each cell line 
represents different phases of PIT-1-dependent cell differentiation in the mouse anterior 
pituitary. The Pit-1/0 cell line, established from a pituitary tumor of a 12 week mouse 
carrying the Pit-Tag transgene and the hGH/bacterial artificial chromosome (BAC) 
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transgene, represents an initial stage of somato-lacto-thyrotropic differentiation. The Pit-
1 gene is expressed, but the cells fail to express the PIT-1-dependent hormones: GH, PRL 
and TSHβ. The Pit-1/Triple cell line, established from a 20 week mouse carrying a Pit-
Tag induced pituitary tumor, represents a more differentiated Pit-1 lineage cell line. 
These cells express PIT-1 protein and its target genes, Gh, Prl and Tshβ. The third cell 
line, the Pit-1/Prl cells were harvested from the pituitary tumor of a mouse carrying both 
the GH-Tag and hGH/BAC transgene. The cells express PIT-1 and Prl, but not GH or 
TSHβ. These PIT-1 lineage cell lines are valuable tools to understand the intermediate 
stages of anterior pituitary development, including epigenetic changes that dictate 
pituitary gene expression. 
1.2.2 LHX3 
 LHX3 (also known as LIM3 or P-Lim) plays a key role in anterior pituitary 
organogenesis, as well as nervous system development (Seidah et al., 1994; Bach et al., 
1995; Zhadanov et al., 1995). In the pituitary, LHX3 is required for the formation of 
somatotropes, thyrotropes, gonadotropes and lactotropes, four of the five distinct 
hormone-secreting cell types. LHX3 activates the transcription of hormone genes, such as 
the αGSU, PRL, FSHβ and gonadotropin-releasing hormone receptor (GnRH-R), as well 
as the PIT-1 transcription factor genes (Savage et al., 2003; Zhu et al., 2007). LHX3 
binds the pituitary glycoprotein binding element (PGBE) of the αGSU gene to activate its 
transcription. In the nervous system, LHX3 interacts with key proteins to establish motor 
neuron and interneuron identity. Interaction between LHX3 and the NLI LIM cofactor is 
associated with V2 interneuron differentiation, while motor neuron development requires 
LHX3 interaction with Islet 1 (ISL1) (Thaler et al., 2002). The critical role that LHX3 
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plays in nervous system and pituitary development is demonstrated by the phenotype of 
Lhx3 gene knockout mice (Lhx3-/-) which die at birth (Sheng et al., 1996). The Lhx3-/- 
mice lack correctly formed anterior and intermediate pituitary lobes, and four of the five 
differentiated hormone-secreting anterior cell types are absent, with only a small 
population of corticotropes remaining (Sheng et al., 1996). Homozygous Lhx3 knockout 
mice also do not undergo proper motor neuron specification (Sheng et al., 1996; Sharma 
et al., 1998).  
The regulation of the Lhx3 gene and LHX3 structure 
 The Lhx3 gene, comprising seven exons and six introns (Figure 2), produces two 
mRNA transcripts: Lhx3a and Lhx3b. The Lhx3 gene contains two TATA-less, GC rich 
promoters that initiate the transcription of Lhx3a and Lhx3b mRNAs. Basal gene activity 
is mediated by the 2 kb and 1.8 kb Lhx3a and Lhx3b promoters, respectively (Yaden et 
al., 2006). The LHX3 promoters contain both nuclear factor 1 (NF1) and specificity 
protein 1 (SP1) transcription factor binding sites and both factors regulate LHX3 
transcription (Yaden et al., 2006). Recently, it has also been shown that SOX2, a 
developmental transcription factor, can bind and activate the human LHX3a promoter 
(Rajab et al., 2008; Alatzoglou et al., 2009).  
 In the human LHX3 gene, a distal enhancer confers some aspects of spatial and 
temporal LHX3 expression in the pituitary and nervous system. A defined 180 bp core 
region (Core R3) of this enhancer guides pituitary-specific expression in model 
transgenes (Mullen et al., 2012). Pituitary Core R3 enhancer activity involves the binding 
of the ISL1 LIM-homeodomain transcription factor, and the pituitary homeobox 1 
6 
 
 
 
(PITX1) transcription factor, as demonstrated by chromatin immunoprecipitation assays 
and mutation of transgenes (Mullen et al., 2012).  
 The LHX3 transcripts are translated to two major protein isoforms, LHX3a and 
LHX3b (Sloop et al., 1999). Each LHX3 isoform possesses distinct DNA binding and 
promoter activation activities (Sloop et al., 1999; Sloop et al., 2001). The LHX3a and 
LHX3b isoforms result from translation of the first methionine codon of the respective 
mRNA (Sloop et al., 1999). The LHX3 protein isoforms have specific domains that exert 
their functions (Figure 3) (Sloop et al., 1999; Parker et al., 2000; Sloop et al., 2001; 
Parker et al., 2005). Both the LHX3 protein isoforms contain a DNA-binding 
homeodomain, two LIM domains, which participate in protein-protein interactions, and a 
carboxyl terminus (C-terminus) trans-activation domain. The DNA-binding 
homeodomain also contains nuclear localization signals that target LHX3 to the nuclear 
matrix (Sloop et al., 1999; Parker et al., 2000). The C-terminus of the LHX3 isoforms is 
divided into three regions, C1, C2 and C3 (Figure 3). The C1 domain contains a nuclear 
localization signal and multiple phosphorylation sites (Parker et al., 2005). LHX3 is a 
predicted substrate of protein kinase C and casein kinase II, and overexpression of these 
kinases leads to a decrease in activation of LHX3 target genes. The C2 region contains a 
trans-activation domain site important for synergy with PIT-1 to activate target 
promoters, such as those of the prolactin and Tshβ genes (Bach et al., 1995; Sloop et al., 
1999; Sloop et al., 2001). The function of the C3 domain has yet to be elucidated.  
The LHX3a isoform acts as a transcriptional activator, while the LHX3b isoform is a 
poor activator of gene transcription and may serve as a repressor (Sloop et al., 1999). 
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 A third protein isoform, M2-LHX3, can be formed by preferential translation of 
the second in-frame methionine codon of the LHX3a mRNA, and is primarily made up of 
the homeodomain plus the C-terminus activation domain (Sloop et al., 2001). Like 
LHX3a, M2-LHX3 can induce transcription of the PRL, αGSU, FSHβ and TSHβ genes 
(Sloop et al., 2001; West et al., 2004). 
2. LHX3 and Combined Pituitary Hormone Deficiency Disease 
 Mutations and gene deletions in human pituitary transcription factor genes have 
been implicated in the etiology of hormone deficiency diseases. Genetic changes 
affecting anterior pituitary transcription factors often lead to negative downstream 
effects, including loss of multiple hormones (Pfaffle and Klammt, 2011). Combined 
pituitary hormone deficiency (CPHD) disease is diagnosed by the insufficiency of GH 
and one or more anterior pituitary hormones (Pfaffle and Klammt, 2011). CPHD patients 
are usually diagnosed as children due to the developmental nature of the affected 
transcription factor(s). Although rare, recessive mutations in LHX3 are responsible for 
some CPHD diagnoses. To date, twelve recessive LHX3 mutations have been molecularly 
and clinically identified as associated with CPHD (Netchine et al., 2000; Bhangoo et al., 
2006; Pfaeffle et al., 2007; Rajab et al., 2008; Kristrom et al., 2009; Bonfig et al., 2011; 
Colvin et al., 2011; Bechtold-Dalla Pozza et al., 2012). Patients with recessive LHX3 
mutations have deficiencies in GH, PRL, TSH, FSH and LH. As a result of the hormone 
loss, patients may exhibit shortness of stature, metabolic defects and delayed/failed 
puberty. Other symptoms may include a hypoplastic, normal or enlarged anterior 
pituitary structure, rigid spine, hearing loss, and ACTH deficiency. Two interesting LHX3 
mutations, T194R and W224Ter, provide insight into the DNA-binding properties and 
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functional domains of the protein, respectively (Pfaeffle et al., 2007; Bechtold-Dalla 
Pozza et al., 2012). Understanding the molecular mechanisms associated with CPHD may 
provide pathways to potential therapies and treatments for patients, while enhancing our 
knowledge of pituitary function.  
2.1 LHX3 T194R 
 Two sibling pediatric patients with CPHD presented with neonatal complications 
and one patient died 20 days after birth due to cardiorespiratory insufficiency. The 
surviving patient presented with sensorineural hearing defect (nervous system 
deficiency), as well as loss of GH, LH, FSH, TSH and PRL, with a later onset of ACTH 
deficiency (pituitary defect). The patients had a homozygous mutation in LHX3 that 
resulted in an amino acid substitution (Bechtold-Dalla Pozza et al., 2012). For each 
patient, sequencing of the LHX3 gene identified a homozygous C→G transversion in the 
fourth coding exon. The transversion changed amino acid 194 from threonine to arginine 
(T194R) in the DNA-binding homeodomain. Sequence analyses demonstrated that the 
threonine residue was conserved among the LHX3/ LIMs proteins of various species, as 
well as in the corresponding position in other human LIM-homeodomain proteins. 
Computer modeling predicated that the T194R substitution would lead to steric 
hindrances, mainly with glutamine 170 and leucine 172, suggesting that the steric 
hindrances may destabilize the tertiary structure of the DNA-binding homeodomain. 
Electrophoretic mobility shift assays (EMSA) showed that LHX3 T194 fails to bind 
known LHX3 target sequences, and the LHX3 T194R did not activate luciferase reporter 
genes under the control of the αGSU and Prl gene promoters (Figure 4).  
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 The T194R mutation is of particular interest because it represents the major class 
of LHX3 mutations in that it affects both pituitary and nervous system development. 
However, one identified LHX3 mutation, W224Ter, is described to only affect pituitary 
development (Pfaeffle et al., 2007). 
2.2 LHX3 W224Ter 
 The LHX3 W224Ter mutation was identified in four siblings of a consanguineous 
Lebanese family (Pfaeffle et al., 2007). The patients presented with pituitary hormone 
deficiency but without the typical cervical spine rigidity that is thought to result from loss 
of LHX3 action in the nervous system. This phenotype therefore is unlike other LHX3 
mutation patients who have both pituitary and nervous system defects. This LHX3 
mutation was result of a G→A transition in position 672 of the LHX3a open reading 
frame, introducing a premature stop codon predicted to cause loss the of the C-terminus 
of the LHX3 protein (Pfaeffle et al., 2007). As described above, the LHX3 C-terminus 
contains trans-activation domains that are critical for pituitary gene regulation (Bach et 
al., 1995; Parker et al., 2000; Sloop et al., 2001) so it is consistent that loss of this protein 
region would lead to pituitary defects. A mouse model of the human LHX3 W224Ter 
disease (Lhx3 W227Ter) was created to determine the molecular and cellular outcomes 
from this mutation (Colvin et al., 2011). Similar to the patients, the mice displayed 
dwarfism, reduced body weight and hypothyroidism (Figure 5). Although patients with 
the W224Ter mutation had reduced FSH, LH and PRL, their inherent reproductive 
potential was unknown due to the necessity of hormone therapy at an early age. The 
female W227Ter mice exhibited infertility, with marked deficiencies in LH, FSH and 
PRL (Figure 5). The phenotype of the Lhx3 W227Ter mouse model demonstrates that the 
10 
 
 
 
molecular actions of LHX3 in the pituitary and nervous system are separable in vivo, as 
well as confirming the role of the LHX3 C-terminus in pituitary development. 
 To further understand the critical role of the LHX3 C-terminus in pituitary gene 
transcription, our lab performed an affinity purification screen to identify proteins that 
interact with the C-terminus. Results from the screen indicated that chromatin-regulating 
proteins interact with the LHX3 C-terminus. However, a general understanding of 
epigenetics is necessary to further define both the interaction of the LHX3 C-terminus 
with the chromatin regulators, as well as regulation of the Lhx3 gene. 
3. Epigenetics 
 Epigenetics can be defined in various ways, depending on the context. Here, it is 
defined as “the structural adaptation of chromosomal regions so as to register, signal or 
perpetuate altered activity states” (Bird, 2007). This definition, presented by British 
geneticist, Dr. Adrian Bird in the introduction of the May 2007 Nature Insight 
Epigenetics issue, aims to unify multiple epigenetic events that occur in a cell.  
3.1 Chromatin structure 
 Genomic DNA is packaged with histone proteins to form chromatin. In the 
canonical model, nucleosomes, the basic unit of chromatin are composed of ~147 bp of 
DNA wrapped around a histone octamer composed of two copies each of the histones 
H2A, H2B, H3 and H4 (Kornberg and Thomas, 1974; Luger et al., 1997). Electrostatic 
interactions and hydrogen bonds between the DNA and histones stabilize nucleosome 
structure. Additionally, histones have a flexible tail, which can interact with neighboring 
nucleosomes or nuclear factors (Luger and Richmond, 1998). Short DNA segments, 
termed linker DNA, connect neighboring nucleosomes to form the primary structure of 
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chromatin, often referred to as “beads-on-a-string” (Oudet et al., 1975; Thoma et al., 
1979; Turner, 2005; Luger et al., 2012). Nucleosomes interact with each other to form 
chromatin fibers, and subsequent fiber interactions lead to highly condensed chromatin. 
Chromatin is organized into two types of conformations, heterochromatin and 
euchromatin (Bassett et al., 2009). Condensed heterochromatin is inaccessible to DNA 
binding factors and is usually transcriptionally silent, whereas decondensed euchromatin 
is generally accessible and transcriptionally active (reviewed by (Grewal and Moazed, 
2003)). Nucleosome modifications, resulting from post-translational modifications of 
histones and DNA methylation, provide a mechanism for the regulation of nuclear 
processes by providing an explanation of how transcription factors access DNA within 
the context of chromatin.  
3.2 Histone modifications 
 Histones are subject to post-translational modifications, chemical modifications of 
amino acid side chains (Berger, 2002). Although there are numerous post-translational 
modifications, histone tails are most commonly modified by phosphorylation, 
SUMOylation, methylation, and acetylation.  
 Histone phosphorylation is linked to multiple cellular processes, including, but 
not limited to chromatin condensation, transcriptional regulation, and apoptosis (Wei et 
al., 1998; Goto et al., 1999; Cruickshank et al., 2010; Mahajan et al., 2012; Park and 
Kim, 2012). Chromatin phosphorylation has been implicated in chromatin condensation 
during the cell cycle. For example, phosphorylation of histone H3 on Ser10 and Ser28 
plays a role in mitotic and meiotic chromosome condensation (Wei et al., 1998; Goto et 
al., 1999). Histone phosphorylation is also linked to apoptosis as demonstrated by the 
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findings that kinase Cδ phosphorylation of histone H3 on Ser10 occurs when cells have 
been exposed to death stimuli (Park and Kim, 2012). An example of histone 
phosphorylation affecting transcriptional regulation is demonstrated by the recent work of 
Mahajan and colleagues, who showed that phosphorylation of histone H2B at T37 by the 
WEE1 kinase leads to the transcriptional suppression of core histone genes (Mahajan et 
al., 2012). The cellular functions altered by histone phosphorylation are extensive, yet the 
above examples provide a glimpse into the diverse complexities of histone 
phosphorylation (Banerjee and Chakravarti, 2011). 
 Another histone modification is SUMOylation, which occurs when a small 
ubiquitin modifier (SUMO) is post-translationally added to proteins. SUMO modification 
has been shown to regulate protein-protein interactions by increasing the affinity of 
interacting proteins, as well as altering the subcellular localization of modified proteins 
(Lomeli and Vazquez, 2011). The addition of the SUMO moiety has also been shown to 
protect proteins from ubiquitin-dependent degradation (Melchior, 2000). With regard to 
histones, Shiio and Eisenman showed that SUMOylation of histone H4 leads to gene 
silencing through the recruitment of histone deacetylase and heterochromatin protein 1 
(Shiio and Eisenman, 2003).  
 A third type of histone modification is methylation, which occurs when histone 
methyltransferases target lysine or arginine residues. A family of nine protein arginine 
methyltransferases (PRMTs) transfer a methyl group to the arginine residue of histone 
proteins, while lysine residues are usually modified by the Su(var)3-9, Enhancer-of-zeste 
and Trithorax (SET) domain family of methyltransferases (Berger, 2002). Histone 
methylation can either activate or repress gene transcription. For example methylation of 
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histone H3 at lysine 9 (H3K9) can be a marker of gene repression, while methylation of 
histone 3 at lysine 4 (H3K4) has been associated with activation of specific genes (Lee et 
al., 2005). 
 Acetylation is a well characterized post-translational histone modification. The 
addition of an acetyl group is catalyzed by histone acetyltransferases (HATs). There are 
three “superfamilies” of HATs: the GNAT (Gcn5-related N-acetyltransferase), the MYST 
(MOZ, Ybf2-sas3, Sas2 and Tip60), and the p300/CREB-binding protein (CBP) families 
(Verdone et al., 2006; Graff and Tsai, 2013). In mammals, the GNAT family has 
homologues in various organisms and is divided into two subfamilies named the GCN5 
acetyltransferases and the p300/CREB-binding associated factors (PCAF) (Verdone et 
al., 2006). Both proteins are associated with HAT activity, but PCAF has also been 
shown to act as a co-activator in cellular processes, such as nuclear-receptor mediated 
activation and hormone promoter regulation (Blanco et al., 1998; Nagy and Tora, 2007; 
Wang et al., 2010; Kino and Chrousos, 2011). In the pituitary TSHβ promoter, cyclic 
adenosine monophosphate (cAMP) treatment led to increased binding of PCAF and p300 
to the promoter, and subsequent increased H4 acetylation, suggesting that recruitment of 
the HATs likely caused the observed acetylation (Wang et al., 2010). The p300/CBP 
HAT subfamily also has roles in hormone and developmental transcription factor 
regulation (Hashimoto et al., 2000; Hashimoto et al., 2005; Miller et al., 2012). 
Hashimoto and colleagues demonstrated that after thyrotropin-releasing hormone (TRH) 
stimulation, LHX3a and CBP synergistically activated the mouse αGSU gene promoter 
(Hashimoto et al., 2005). PIT-1 has also been shown to recruit coactivator complexes 
containing CBP/p300 to activate gene transcription (Xu et al., 1998; Zanger et al., 1999). 
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Histone acetylation is important for regulation, so it follows that the modification is 
reversible. 
 Histone deacetylases (HDACs) catalyze the removal of the acetyl group from 
histones. Proteins with HDAC activity can be divided into three main classes based on 
homology with the yeast proteins: Rpd3, Hos 1 and Hos 2 (class I), HDA1 and Hos3 
(class II) and the sirtuins (class III) (Gallinari et al., 2007). HDAC11, found in higher 
eukaryotes, is regarded as a separate class (class IV) due to its different phylogenetics 
(Gallinari et al., 2007). Class III HDACs depend on NAD+ as a cofactor for the transfer 
of the acetyl group, whereas class I, II and IV enzymes depend on a zinc-catalyzed 
hydrolysis of the acetyl-amide bond by a zinc (de Ruijter et al., 2003). 
 HDACs interact with other proteins to modulate gene expression. In the pituitary, 
histone H4 is deacetylated by the ligand-dependent recruitment of the glucocorticoid 
receptor (GR) and HDAC2 to the POMC locus, leading to gene repression (Bilodeau et 
al., 2006). HDACs have also been identified as members of corepressor complexes, 
including mSin3A, NURD/Mi2/NRD and CoREST corepressor complexes (Gallinari et 
al., 2007). Similar to nuclear receptors, the PIT-1 protein can interact with both co-
repressor and co-activator complexes to modulate gene expression (Scully et al., 2000; 
Voss et al., 2005). PIT-1 interacts with the NCoR complex, which associates with HDAC 
proteins to modify chromatin structure and repress gene transcription (Xu et al., 1998; 
Scully et al., 2000; Voss et al., 2005). Wen and colleagues demonstrated that HDAC3 is 
involved in the NCoR mediated repression of PIT-1 (Wen et al., 2000). HDACs also 
associate with other chromatin remodeling proteins, such as the inhibitor of histone 
acetyltransferase (INHAT) complex (Kutney et al., 2004a).  
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3.2.1 Interactions of the LHX3 C-terminus with the chromatin regulating complex, 
inhibitor of histone acetyltransferase (INHAT)  
 As described earlier, the LHX3 C-terminus contains important activation and 
signaling domains (Figure 3). To further understand the role of the LHX3 C-terminus in 
pituitary gene regulation, putative proteins that interact with the LHX3 C-terminus were 
identified by an affinity purification approach coupled with mass spectrometry. Leucine-
rich acidic nuclear protein (LANP) and template activating factor-1β (TAF-1β), members 
of the INHAT complex, were identified as putative proteins that interact with the C-
terminus of LHX3. INHAT is a multi-subunit complex that inhibits histone acetylation 
and modulates chromatin structure.  
 INHAT is composed of two main subunits, LANP and TAF-1β. LANP, also 
known as pp32, PHAP-1, mapmodulin or I1PP2A, is a 28.5 kDa tumor suppressor 
protein (Li et al., 1996). It has a leucine-rich amino terminal and a long C-terminal acidic 
domain that inhibits histone acetylation (Seo et al., 2002). LANP has other postulated 
roles in the cell, including neuronal differentiation, RNA shuttling, microtubule-based 
functions, apoptosis and inhibition of protein phosphatase 2A (PP2A) (Matilla and 
Radrizzani, 2005; Kular et al., 2009). LANP also binds ataxin 1, a polyglutamine protein 
that is linked to neurodegenerative diseases (Matilla et al., 1997). The other INHAT 
subunit, TAF-1β is a 39 kDa histone chaperone encoded by the myeloid leukemia-
associated oncogene SET (Nagata et al., 1995). SET was identified as a novel 
translocation in a leukemia patient “SE” (von Lindern et al., 1992). Like LANP, TAF-1β 
has a long acidic tail, which also participates in histone acetyltransferase inhibition (Seo 
et al., 2001). TAF-1β also has various other suggested functions in the cell, such as 
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inhibition of PP2A, apoptosis and cell cycle regulation (Li et al., 1996; Estanyol et al., 
1999). 
 Our lab used molecular and biochemical techniques to characterize the INHAT-
LHX3 interaction. Glutathione S-transferase (GST)-interaction assays demonstrated that 
the acidic tails of TAF-1β and LANP interact with LHX3, while chromatin 
immunoprecipitation assays revealed that the INHAT complex occupies the αGSU gene 
pituitary glycoprotein binding element (PGBE), a critical gene regulatory element 
recognized by LHX3 (Figure 6). Other studies have shown that INHAT proteins 
participate in gene repression (Seo et al., 2001; Kutney et al., 2004b; Telese et al., 2005; 
Macfarlan et al., 2006). Similarly, our data also indicate LHX3, LANP, and TAF-1β 
associate with the LHX3-responsive αGSU promoter in mouse gonadotrope cells, and 
LHX3-driven pituitary gene activation is inhibited by INHAT protein overexpression. 
However, interactions between INHAT and LHX3 may also prevent gene repression by 
INHAT. In this model, interactions of the LHX3 C-terminus with the acidic domains of 
TAF-1β and LANP disrupt the INHAT complex, leading to its disassociation from the 
promoter. The dissociation of INHAT would then allow for subsequent trans-activation 
of the gene target by LHX3 and possibly the global co-activator CBP, which has 
previously been shown to interact with LHX3 (Hashimoto et al., 2005). Thus, LHX3 may 
work both indirectly by disrupting core INHAT proteins in a “de-repression” function 
and directly by serving as a DNA-binding transcription factor on pituitary target genes. 
Collectively, the INHAT-LHX3 interaction suggests coordinated interplay between the 
cellular microenvironment and the developmental transcription factor, LHX3.  
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3.3 DNA methylation 
 DNA methylation represents another level of transcriptional control and 
regulation in the cell. DNA methyltransferases (DNMTs) catalyze the addition of a 
methyl group to the 5′ position of the cytosine pyrimidine ring of CpG (cytosine-
phosphate bond-guanine) dinucleotides (Ramsahoye et al., 1996; Robertson and Jones, 
2000). CpG islands are CG dense regions (~1 CpG per 10 bp) that are usually resistant to 
methylation and account for ~2% of CpG of the human genome (Illingworth et al., 2008; 
Smith and Meissner, 2013). However, the promoters of some developmental genes, such 
as Hox genes, have been shown by mapping experiments to have methylated CpG islands 
(Illingworth et al., 2008; Auclair and Weber, 2012).  
 DNA methylation has various roles in the cell, such as chromatin silencing, 
female X chromosome inactivation, the imprinting of parental alleles, viral gene 
inactivation and silencing of individual genes (Ramsahoye et al., 1996; Dulac, 2010). 
Some methylation patterns are cell heritable, meaning the maintenance methyltransferase 
DNMT1 uses the methylation pattern of the original DNA strand as a template for 
catalyzing a symmetric methylation pattern on a newly synthesized DNA strand (Otto 
and Walbot, 1990). Because of its role in maintenance methylation, DNMT1 is a critical 
enzyme during development. In mice, targeted mutation of the Dnmt1 gene is embryonic 
lethal, with mice not surviving past mid-gestation (Li et al., 1992).  
 Another type of DNA methylation, appropriately known as de novo methylation, 
establishes new patterns of methylation in cells (Zhang and Ho, 2011). It is particularly 
important for early development and gametogenesis and involves DNMT3 
methyltransferases (Jahner et al., 1982; Stewart et al., 1982; Okano et al., 1999). In mice, 
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the Dnmt3 family is composed of the Dnmt3a and Dnmt3b genes. These genes are 
essential for development, as Dnmt3a-/- mice die four weeks after birth and Dnmt3b-/- 
mice die mid-gestation (Okano et al., 1999). Interestingly, targeted mutation of the 
murine Dnmt2 gene does not alter de novo or maintenance methylation of proviral DNA, 
suggesting it is not involved in global de novo DNA methylation (Okano et al., 1998). 
3.3.1 Methyl CpG binding proteins  
 DNA methylation, both maintenance and de novo, establishes another platform 
for cellular regulation. It can serve as a marker or signal for transcription factors, or other 
binding proteins, such as methyl CpG-binding proteins. Methyl-CpG binding proteins 
(MBPs) bind methylated DNA and recruit regulatory proteins to modulate chromatin 
structure and gene activity (Buck-Koehntop and Defossez, 2013). These proteins can be 
divided into two main families based on structural homology: methyl-CpG binding 
domain proteins (MBDs) and zinc-finger proteins (Bogdanovic and Veenstra, 2009; 
Buck-Koehntop and Defossez, 2013).  
MBD proteins 
 The MBD family is composed of MeCP2, MBD1, MBD2, MBD3, MBD4, MBD5 
and MBD6. However, MBD3, MBD5 and MBD6 do not directly bind methylated DNA 
and certain splice variants of MBD1 have been shown to bind unmethylated DNA as well 
(Fujita et al., 2000; Saito and Ishikawa, 2002; Laget et al., 2010). The MBD family is 
primarily associated with transcriptional repression mechanisms, but MBD1 and MBD4 
have additional functions in DNA repair (Bellacosa et al., 1999; Watanabe et al., 2003). 
MeCP2 was the first MBD protein discovered and homology searches using the amino 
acid sequence of the MeCP2 MBD domain led to the discovery of MBD1, MBD2, MBD3 
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and MBD4 (Cross et al., 1997; Hendrich and Bird, 1998). MeCP2 is involved in both 
transcription repression and activation, with its activity dependent on the specific 
chromatin microenvironment (Klose and Bird, 2004; Bogdanovic and Veenstra, 2009). 
For example, MeCP2 has been shown to recruit chromatin remodeling complexes, such 
as Sin3a and repress transcription at the promoter of brain-derived neurotrophic factor 
(BDNF) (Chen et al., 2003; Martinowich et al., 2003; Klose and Bird, 2004). Mutations 
in MeCP2 are associated with Rett Syndrome, an X-linked neurodevelopment disorder in 
females (Amir et al., 1999).  
 The zinc finger methyl-binding proteins include Kaiso, ZBTB4 and ZBTB38, and 
like the MBDs are associated with transcriptional repression (Bogdanovic and Veenstra, 
2009). Kaiso is a nuclear protein, first discovered to interact with p120 catenin (Daniel 
and Reynolds, 1999). Prokhortchouk and colleagues later identified Kaiso as a 
methylation-specific DNA binding protein with transcriptional repression activity 
(Prokhortchouk et al., 2001). The Kaiso protein belongs to the BTB/POZ (broad 
complex, tramtrak, bric à brac/pox virus and zinc finger) subfamily (Buck-Koehntop et 
al., 2012). The zinc finger domain recognizes DNA and the BTB/POZ domain mediates 
protein-protein interactions. Kaiso has three Cys2His2 zinc fingers with two recognizing 
methylated CpG dinucleotides and the other recognizing the consensus sequence 
TCCTGCNA (KBS motif) (Buck-Koehntop et al., 2012). The other two zinc finger 
methyl-binding proteins, ZBTB4 and ZBTB38 contain Kaiso-like zinc fingers, but unlike 
Kaiso they can bind single methylated CpGs (Filion et al., 2006).  
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3.4 MeCP2 and chromatin cross-talk 
 While it is necessary to understand the inherent properties of individual 
transcriptional regulators, it is the cross-talk between these factors that is helpful in 
elucidating mechanisms of transcriptional regulation. The interactions between DNA 
methyl-binding proteins and histone modifying proteins are essential for coordinated 
transcriptional regulation in cells. A general understanding of communication within the 
chromatin microenvironment of various cell types is imperative for identifying potential 
regulatory mechanisms in the pituitary, as these interactions may modulate the 
development, production and release of hormones. Multiple studies have associated 
various methyl-binding proteins with histone modifying complexes (reviewed by 
(Vaissiere et al., 2008; Bogdanovic and Veenstra, 2009)), but the interactions of MeCP2 
with methylated DNA are the main focus of this dissertation.  
 The Cedar laboratory conducted one of the first studies linking chromatin 
structure with DNA methylation by examining protein-DNA interactions of mouse cells 
transfected with methylated or unmethylated DNA (Keshet et al., 1986). Using DNase I-
sensitivity assays, they showed that unmethylated DNA integration formed DNase I-
sensitive conformations, whereas methylated DNA integration prevented formation of the 
structure (Keshet et al., 1986). These findings suggested that the inhibitory effects of 
DNA silencing involve alterations in protein-DNA interactions, and thus implicated 
histones and other transcription factors in the mechanism.  
 Studies examining the interactions of methyl-binding proteins with chromatin 
modifiers, including HDACs and co-repressor complexes confirmed cross-talk between 
DNA methylation and chromatin in regulating gene expression. For example, studies in 
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Xenopus and mice have demonstrated that MeCP2 interacts with Sin3 and histone 
deacetylase to trigger deacetylation of histones (Jones et al., 1998; Nan et al., 1998). As 
mentioned earlier, one study demonstrated that MeCP2 recruited the mSin3a-HDAC1 
complex to repress transcription of the BDNF promoter in cortical cells (Chen et al., 
2003; Martinowich et al., 2003; Klose and Bird, 2004). MeCP2 can also interact with 
histone methyltransferases to mediate repression (Lunyak et al., 2002; Fuks et al., 2003). 
MeCP2 has been identified as a participant in neuronal gene repression, and the 
Rosenfeld lab performed a two stage chromatin immunoprecipitation assay to show that 
both MeCP2 and the histone H3 lysine 9 (H3K9) methyltransferase, SUV39H1 bind the 
neuronal type II sodium channel (NaCh II) promoter in Rat-1 cells (Lunyak et al., 2002). 
The lab also used ChIP assays to show that MeCP2, the CoREST co-repressor complex 
and SUV39H1 are present on the same NaCh II transcription units. In a separate study, 
Fuks and colleagues showed that MeCP2 enriched histone H3K9 methyltransferase 
activities in 293T cells (Fuks et al., 2003).  
 Although there is substantial evidence of the role of MeCP2 in gene repression, 
some studies suggest MeCP2 interacts with chromatin modifying proteins to activate 
genes (Jones et al., 1998; Nan et al., 1998; Lunyak et al., 2002; Chen et al., 2013). A 
recent study showed that MeCP2 recruits CREB1 to activate the murine neuronal glucose 
transporter isoform 3 (glut3) gene in murine neurons (Chen et al., 2013). Microarray 
analysis of hypothalamic tissue from MeCP2 null mice and mice that overexpress MeCP2 
(MECP2-Tg mice) indicated that approximately 85% of genes appeared to be activated 
by MeCP2 (Chahrour et al., 2008). Additionally, CREB1 co-immunoprecipitated with 
MeCP2 from mouse brain extracts, and functional assays demonstrated that co-
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transfection of CREB1 and MeCP2 enhanced somatostatin reporter activity in Neuro2a 
cells (Chahrour et al., 2008).  
 Other studies have implicated MeCP2 in modulating chromatin architecture 
(Ghosh et al., 2010; Skene et al., 2010; Baker et al., 2013). MeCP2 has been shown to 
bind linker DNA, induce nucleosome conformational changes (primarily extensive 
nucleosome packing) and form a competitive equilibrium with histone H1 for chromatin 
binding (Ghosh et al., 2010). In neurons, MeCP2 has been suggested to act as an alternate 
histone linker (Skene et al., 2010), as well.  
 Communication involving DNA methylation and histone complexes in the 
pituitary have yet to be elucidated, but data from Martinowhich and Sun indicate that 
MeCP2 binds the Pomc promoter (Tao et al., 2009). To further understand transcriptional 
regulation of gene expression in pituitary cells, future studies need to explore the 
interactions of DNA methylation and chromatin architecture in the pituitary. 
4. Focus of Dissertation 
 LHX3 is a critical regulator of pituitary and nervous system development. The 
coordinated and controlled molecular mechanisms involved in its transcription regulate 
its expression. Interestingly, LHX3 is differentially expressed in murine pituitary cell 
lines representing distinct stages of pituitary differentiation. DNA methylation is often 
associated with differential gene expression, but the epigenetics associated with Lhx3 
gene expression have yet to be explored. Therefore, the focus of this dissertation is on the 
role of DNA methylation in regulating Lhx3 gene expression in the murine pituitary Pit-
1/0 precursor cell line. The demethylating reagent 5-Aza-2’-deoxycytidine (5-aza-dc) is 
commonly used to examine DNA methylation, since it inhibits DNMTs from methylating 
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DNA (reviewed by (Christman, 2002)). Gene activation resulting from treatment with 5-
aza-dc and the HDAC inhibitor, trichostatin A (TSA) has also been demonstrated in 
multiple studies and thus provides a tool to study cross-talk between DNA methylation 
and histone modifiers (Cameron et al., 1999; Bovenzi and Momparler, 2001; Yu et al., 
2010). This dissertation examines patterns of DNA methylation of the Lhx3 promoters, 
examines the effect of 5-aza-dc and TSA on Lhx3 gene expression, and identifies an 
association between the Lhx3 promoters and MeCP2 in the mouse Pit-1/0 cell line. 
Understanding the epigenetics of the Lhx3 gene is important because dysregulation or 
mutations of the LHX3/Lhx3 gene results in syndromic pediatric diseases such as CPHD.  
24 
 
 
 
Fi
gu
re
 1
. T
ra
ns
cr
ip
tio
n 
ca
sc
ad
e 
go
ve
rn
in
g 
an
te
ri
or
 p
itu
ita
ry
 d
ev
el
op
m
en
t (
M
ul
le
n 
et
 a
l.,
 2
00
7;
 C
ol
vi
n 
et
 a
l.,
 
20
11
). 
A
P=
 a
nt
er
io
r p
itu
ita
ry
, I
P 
= 
in
te
rm
ed
ia
te
 p
itu
ita
ry
, P
P=
 p
os
te
rio
r p
itu
ita
ry
, r
R
P=
 ru
di
m
en
ta
ry
 R
at
hk
e’
s 
po
uc
h.
  
25 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The LHX3 gene. The human LHX3 gene is located on chromosome 9 and 
produces two major mRNAs (LHX3a, LHX3b) encoding three protein isoforms (LHX3a, 
LHX3b, and M2-LHX3) with distinct activities (Sloop et al., 1999; Sloop et al., 2001). 
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Figure 3. LHX3 “functional domains” (Sloop et al., 1999; Parker et al., 2000; Bridwell 
et al., 2001; Parker et al., 2005). A, B, M2: alternate amino termini. C1, C2, C3: carboxyl 
terminal regions. Red boxes: nuclear localization signals. Phosphorylation sites indicated 
in blue. 
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Figure 4. Biochemical analysis of the T194R “mutant” form of LHX3. (A, B) The 
LHX3 T194R protein does not bind to LHX3 DNA recognition elements. EMSA 
experiments were performed using the WT or T194R LHX3 proteins translated in vitro in 
rabbit reticulocyte lysates and radiolabeled DNA probes representing the LHX3 
consensus-binding site (Bridwell et al., 2001) (A) or the αGSU promoter pituitary 
glycoprotein-binding element (B). Unprogrammed lysates were used as negative controls 
(Control). The LHX3/DNA complexes are denoted by arrowheads. F = Free probe. (C, 
D) The LHX3 T194R protein is unable to activate pituitary target genes. Expression 
vectors for wild type (WT) and T194R LHX3 proteins were transiently cotransfected into 
mouse pituitary GHFT1 cells with a luciferase reporter gene under the control of the 
mouse alpha glycoprotein (αGSU) promoter (C). Promoter activity was assayed by 
measuring luciferase activity 48 h after transfection. Negative controls (Control) received 
equivalent amounts of empty expression vector plasmid. Activities are mean (light 
units/10 s/g total protein) of triplicate assays ± SEM. A representative experiment of at 
least three experiments is depicted. Similar experiments to those depicted in (C) were 
performed using a rat prolactin (PRL) promoter/enhancer reporter gene (D). Adapted 
from (Bechtold-Dalla Pozza et al., 2012). 
A B C D 
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Figure 5. Lhx3W227ter/W227ter mice are dwarfed and have a PRL deficiency. (A) Growth 
deficiency of male homozygote Lhx3W227ter/W227ter mice becomes significant at postnatal 
day 21 (P21) compared to controls. Asterisks (*) indicate a significant difference between 
Lhx3W227ter/W227ter compared with wild-type (+/+) and heterozygote controls with P < 0.05 
(ANOVA). Error bars are ±SEM. Inset shows Lhx3+/+ (Left) and Lhx3W227ter/W227ter (Right) 
male litter mates at 8 wk old. (B) Real-time quantitative PCR analyses demonstrate a 
reduction in Prl transcripts in Lhx3W227ter/W227ter pituitaries (KI/KI) relative to wild-type 
(+/+) and heterozygote (+/KI) counterparts at 12 wks of age. Data are mRNA levels 
normalized to a control transcript (36b4). Error bars are ±SEM. Asterisk (*) indicates 
significance compared with wild-type controls with P < 0.05 or less (Student's two-tailed 
T-test). (C) Western blot detection of PRL protein in 12-wk pituitaries confirms the PRL 
deficiency in the Lhx3W227ter/W227ter mutant mice compared with wild-type controls. Blots 
were reprobed with an anti-GAPDH antibody as a loading control. Adapted from (Colvin 
et al., 2011).  
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Figure 6. Characterization of the LHX3-INHAT relationship. (A) Affinity 
purification scheme for purifying LHX3 carboxyl terminus interacting proteins from 
cellular extracts using GST fusions bound to a solid support. GST alone and GST-LHX3 
carboxyl-terminus bound proteins were compared via mass spectroscopy or western 
blotting. (B) Elutions from affinity purifications were tested by western blotting for 
enrichment of INHAT proteins. (C) The LANP and TAF-1β INHAT proteins are 
associated with the LHX3-bound αGSU gene promoter. Chromatin immunoprecipitation 
(ChIP) was used to probe occupancy of the pituitary glycoprotein binding element 
(PGBE) region of the mouse αGSU promoter (Roberson et al., 1994; Bach et al., 1995) 
by LANP, TAF-1β (left) or LHX3 (right) proteins in LβT2 pituitary cells. ChIP 
enrichment was measured by quantitative PCR and represented as percent input, 
calculated by 100*2^(input - Ct (IP)). Values are mean ± SEM for three independent 
experiments. Immunoprecipitation with non-immune species-matched IgG were carried 
out as negative controls. Adapted from Hunter/Malik et al. (submitted 2013). 
LANP 
TAF1β 
control 
glutathione 
agarose-GST 
 
precleared  
pituitary cell  
extract 
non-specific  
interactors 
Glutathione- 
agarose- 
GST-LHX3 
C-terminus 
precleared  
pituitary cell  
extract 
non-specific  
interactors 
 
SDS-PAGE Mass Spec. 
A 
B 
C 
30 
 
 
 
Methods 
1. Bioinformatic Analysis 
 EMBOSS CpGPlot (http://www.ebi.ac.uk/Tools/emboss/cpgplot/) was used to 
determine potential CpG islands in the mouse and human Lhx3 gene. Mouse and human 
Lhx3/LHX3 gene sequences (UCSC Genome Bioinformatics, http://genome.ucsc.edu/), 
spanning -3.5 kb upstream and 8 kb downstream of the translation start site were used as 
input. The minimum length of the reported CG was 200 bp. The observed to expected 
ratio (Obs/Exp) of C plus G to CpG in a set of 10 windows required before a CpG island 
is reported was 0.6. DNAsis Software was used to analyze the Lhx3 sequences.  
2. Cell Culture 
 The Pit-1/0 and Pit-1/Triple cell lines (Sizova et al., 2010) a generous gift from 
Dr. R. Day, IUSM) were maintained in Dulbecco’s Modified Eagle’s Media/Ham’s 
Nutrient Mixture F-12 (1:1) with 2.5 mM L-glutamine (Hyclone, Logan UT) 
supplemented with 10% heat-inactivated fetal bovine serum (Biowest, Nuaillé, France) 
and antibiotic-antimycotic (Invitrogen, Gran Island, NY). The cells were grown at 37°C 
in humidified 5% CO2containing atmosphere.  
3. Cell Treatments  
 Cells (1x106 cells/10 cm) were plated and 24 h later treated with 5-aza-2’-
deoxycytidine (2.5 μM 5-aza-dc, Sigma-Aldrich, St. Louis, MO) or 5-aza-dc (2.0 μM) 
plus Trichostatin A (100 nM, TSA) in media containing 10% FBS. Cells treated with 5-
aza-dc plus TSA were harvested 24 h after treatment, while cells treated with only 5-aza-
dc were harvested 48 h after treatment. Control plates were treated with DMSO (100 μl) 
as vehicle. 
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4. Bisulfite Genomic Sequencing 
 Genomic DNA was isolated from treated and untreated Pit-1/0 cells and Pit-
1/Triple cells using a PureLink Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s protocol. The bisulfite conversion was carried out with 
500 ng of input genomic DNA with the use of the EZ DNA Methylation-Gold Kit 
(Zymo Research Corp., Orange, CA) following the manufacturer’s protocol. Supplied 
Conversion Reagent (130 μl) was added to 20 μl of DNA (500 ng). The sample was 
subjected to thermal cycling with the following parameters per kit instructions: 98°C for 
10 m, 64°C for 2.5 h and 4°C for up to 20 h. The sample was then mixed with binding 
buffer and applied by centrifugation to the Zymo-Spin™ ion chromatography (IC) 
column. The bound materials were washed and desulphonation buffer was added to the 
column. After incubating the column for 15 m the sample was centrifuged and washed. 
The bisulfite converted DNA was eluted in a volume of 10 μl RNase free water and then 
diluted 1:10 for a final volume of 50 μl. The bisulfite converted DNA (5 μl) was 
amplified by PCR using the Fast Start High Fidelity PCR System (Roche, Mannheim, 
Germany) with specific primers to the Lhx3a and Lhx3b promoters. Primers designed 
using the MethPrimer software (http:/ww.urogene.org/methprimer/) were as follows: 
mLhx3a promoter forward, 5′- ggaaggttagagaaaaggttattt-3′; mLhx3a promoter reverse, 5′-
aaaaaacaaaaactccaaaaacac-3′; mLhx3b promoter forward, 5′-gtatttgtaggaagttttgagtggtatt-
3′; Lhx3b promoter reverse, 5′- ccctaaacttcccctaaatctaac-3′. A ‘hot’ start PCR was 
performed by initially heating the reaction to 95°C for 2 m, prior to the addition of 
enzyme. The reaction then underwent 40 cycles of 95°C for 2 m, 59°C for 30 sec., 72°C 
for 1 m, and a final extension time 7 m. The PCR products were gel purified using a 
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Qiaquick gel extraction kit (Qiagen, Valencia, CA), then sub-cloned into the pCR-4 
TOPO vector using the TOPO TA Cloning kit (Invitrogen, Grand Island, NY). The 
plasmid was transformed according to the manufacturer’s protocol. Briefly, E.coli DH5α 
cells (50 μl) and plasmid DNA (2 μl) were incubated on ice for 15 m. The reaction 
mixtures were heat shocked at 42°C for 45 seconds followed by incubation on ice for 2 m 
Super Optimal Broth (SOC, Invitrogen, Grand Island, NY) was added and the cells were 
incubated with shaking at 37°C for 0.5-1 h. Cells were then plated on antibiotic 
appropriate LB agar plates. Plasmid DNA from at least 15 unique colonies per group was 
prepared using PureLink Quick Plasmid Miniprep (Invitrogen, Grand Island, NY) and 
sequenced (ACGT, Inc, Wheeling, IL) using M13 Forward (-20) universal primer.  
5. RNA Isolation and Reverse Transcription 
 Endogenous or treated Pit-1/0 cells (1x106 cells/10 cm plate) and Pit-1/Triple cells 
(1x106 cells/10 cm) were plated and RNA was harvested 24 h later. Total RNA was 
extracted using the RNAeasy Mini Kit (Qiagen, Hilden, Germany) following the 
manufacturer’s protocol. Complementary DNA (cDNA) was synthesized from 1 μg of 
total RNA using High Capacity Reverse Transcription kit (Applied Biosystems, Grand 
Island, NY) according to the manufacturer’s protocol. The cDNA was used as a template 
for PCR reactions performed with GoTaq Green Master Mix (Promega, Madison, WI). 
Primers used were as follows: mLhx3a forward, 5′- aaccactggattagtgactg-3′; mLhx3b 
forward, 5′-gaagttcagggtcggaggg-3′; mLhx3a/b reverse, 5′- tggtcacagcctgcacacat-3′; β-
actin forward, 5′-ctacaatgagctgcgtgtgg-3′; β-actin reverse, 5′-tagctcttctccagggagga-3′; 
αGSU forward, 5′-aatcacctgcccagaacacat-3′; αGSU reverse 5′-agcgcgtcagaagtctggta-3′; 
TSHβ forward 5′-tactgcctgaccatcaacac-3′; TSHβ reverse 5′-ttctgacagcctcgtgtatg-3′. The 
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PCR parameters were as follows: 95°C for 2 m, 40 cycles of 95°C for 30 sec., 55-58°C 
for 1 m, 72°C for 1 m, and a final extension time of 72°C for 7 m. The PCR products 
were analyzed on the Mini-PROTEAN 10% TBE precast gels (Biorad, Hercules, CA) by 
electrophoresis. 
6. Protein Analysis 
6.1. Protein isolation  
 Whole cell protein extracts of Pit-1/0 cells (1x107 cells/15 cm plate) and Pit-
1/Triple cells (1x107 cells/15 cm) were isolated for Western blotting. Briefly, the cells 
were rinsed with cold PBS and harvested in one ml cold PBS. The cells were centrifuged 
for one minute at 6,000 x g and the PBS was removed. The cell pellet was suspended in 
RIPA Lysis buffer (150 mM NaCl, 2mM EDTA, 1% NP-40, 1% sodium deoxycholate, 
0.1% SDS, 0.01 sodium phosphate, pH 7.2, 50 mM NaFl) containing protease inhibitors 
(Complete Mini protease inhibitor cocktail tablet, Roche, Mannheim, Germany) and the 
cells were lysed on ice for 15 m After incubation, the sample was centrifuged at 13,000 x 
g for 10 m. Supernates were aliquoted and stored at -20°C. The BCA Protein Assay 
(Thermo Scientific, Rockford, IL) was used to determine protein concentration.  
6.2. Western blot 
 The harvested protein (25 μg) was subjected to SDS polyacrylamide gel 
electrophoresis (SDS-PAGE; 12%; 100V). After electrophoresis, gels were equilibrated 
for 5 minutes in western transfer buffer (192 mM glycine, 2 mM Tris, 20% methanol). 
PVDF membranes were charged in methanol, prior to transfer. The transfer apparatus 
was assembled according to the manufacturer’s instructions (Biorad). Protein was 
transferred at 80 mAmps in 4°C with an ice block. After transfer, the PVDF membrane 
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was washed with TBST (Tris-Buffered Saline Tween (154 mM NaCl, 52 mM Tris, 1% 
Tween 20) with shaking. The membranes were blocked in 5% nonfat dry milk (NFDM, 
Carnation) in TBST for 1 h with shaking. After blocking, the membranes were washed 3x 
5 m each with TBST. Each membrane was then incubated with LHX3 (Chemicon, 
Temecula, CA; 1:2,500), MBD2 (Abcam, Cambridge, MA; 2 μg/μl) or MeCP2 primary 
antibody (Abcam; 2 μg/μl) in TBST overnight at 4°C with shaking. The membrane was 
washed 3x 5 m with TBST and then incubated with an appropriate peroxidase conjugated 
secondary antibody (1:25,000) in TBST for 1 h. Bound antibody was visualized with 
SuperSignal West Dura Extended Duration Substrate (Thermo Scientific) for 1 m with 
gentle mixing prior to documentation by G-Box Imaging System (Syngene, Frederick, 
MD).  
7. Chromatin Immunoprecipitation Assay 
 Pit-1/0 chromatin was isolated for chromatin immunoprecipitation (ChIP) 
analysis. Pit-1/0 cells (~1-2 x 107 ) were grown in 15 cm culture dishes and treated with 
5-aza-dc (2.5 μM), 5-aza-dc (2.0 μM) plus TSA (100 nM) or DMSO vehicle (100 μl). 
Twenty-four hours after treatment, the chromatin was isolated from the control plate and 
2.0 μM 5-aza-dc plus 100 nM TSA treated cells. Cells from the 5-aza-dc only treatment 
group were harvested 48 h post treatment. ChIP assays were carried out with the EZ ChIP 
Kit (Millipore, Billierica, MA) following the manufacturer’s protocol. Each 15 cm dish 
of Pit-1/0 cells was washed twice with filtered phosphate buffered saline (PBS) The 
chromatin was crosslinked with 1% formaldehyde (Thermo Scientific, 16% Stock) 
prepared in PBS for 8 min at room temperature. The crosslinking reaction was terminated 
with the addition of glycine (2.5 μM) followed by a 5 m incubation at room temperature. 
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The media was aspirated and cell monolayers were washed two times with cold PBS. The 
cells were then quantitatively transferred in cold PBS (1.0 ml) to a 1.5 ml tube on ice and 
centrifuged at 4,000 x g for 5 m at 4°C. Cell pellets were resuspended in SDS Lysis 
Buffer (200 μl/ per 1 million cells), supplemented with PMSF and incubated on ice for 
10m. The lystes were subjected to sonication (3 x 11 m; on 30 s, off 30 s) using a water 
bath sonicator. After sonication, the samples were centrifuged at 13,000 x g for 10 m at 
4°C and the supernates were aliquoted (200 μl). A 20 μl aliquot was used to check for 
shearing efficiency. Briefly, 30 μl of TE was added to the 20 μl aliquot for a total volume 
of 50 μl. Crosslinks were reversed by adding 5 M NaCl (2 μl) to the sample and 
incubating it at 65°C overnight. The sample was treated with RNase (1 μl; 10mg/ml) for 
15 m at 37°C. To remove proteins, Proteinase K (1 μl; 10 mg/ml) was added and the 
sample was incubated at 45°C for 1-2 h The sheared samples were analyzed on 1.5% 
agarose gel to check the generation of DNA fragments (<1 kb). 
 Chromatin isolated from Pit-1/0 cells (200 μl) was mixed with cold dilution buffer 
containing protease inhibitors. The samples were precleared for 1 h with Salmon Sperm 
DNA Blocked Protein A agarose beads (60 μl, Millipore). An input control sample was 
removed (1%) from the precleared chromatin and stored at 4°C for downstream PCR 
analysis. Supernates were incubated with antibody (5 μg) overnight with gentle shaking. 
The following antibodies were used: anti-acetyl Histone 3 (Millipore, Temecula, CA), 
MeCP2 (Abcam, Cambridge, MA), MBD2 (Abcam) and rabbit IgG as a negative control. 
Following the overnight incubation, Protein A beads (60 μl) were added and the samples 
were incubated at 4°C for 2-4 h. In accordance with the manufacturer’s protocol, the 
beads were washed for 5 m with 1 ml of each solution provided in the kit in the order 
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listed at 4°C: low salt buffer, high salt buffer, LiCl buffer and two washes with TE. The 
sample was eluted with elution buffer containing SDS and NaHCO3 and purified using 
columns provided in the ChIP kit.  
 Relative abundance of regions of interest in precipitated DNA was measured by 
quantitative PCR (qPCR) (ABI 7900 PRISM, Applied Biosystems, Foster City, CA) 
using SYBR green (Roche). The isolated ChIP input DNA was diluted 1:10 and primers 
to the Lhx3 promoter were as follows: Lhx3a forward, 5'-tgaaagaggtccagcacttcc-3'; Lhx3a 
reverse, 5'-tggcaatcgagttctgcttc-3'; Lhx3b forward, 5'-tctgtaggaagccttgagtgg-3'; Lhx3b 
reverse, 5'-cgtctggcttgcacttcc-3'. The PCR parameters were as follows: 95°C 15 m for one 
cycle, 95°C 15 sec, 60°C 60 sec for 40 cycles and 95°C 15 sec, 60°C 1 m, 95°C 15 sec 
for one cycle. Fold enrichment was calculated using the following formula: 2^-[Ct(IgG) –Ct-
(sample)] 
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Results 
1. Analysis of Lhx3 mRNA and LHX3 Protein Expression 
 Recently, mouse cell lines representing different stages of anterior pituitary cell 
development have been generated using pituitary promoters to target immortalizing genes 
in transgenic animals (Sizova et al., 2010). Of these, the Pit-1/0 and Pit-1/Triple lines 
represent earlier and later developmental stages, respectively. Unfortunately, similar 
reagents modeling human pituitary cell types are not available. To examine whether the 
Lhx3a and Lhx3b mRNAs are expressed in Pit-1/0 and Pit-1/Triple cells, total RNA was 
isolated and Lhx3a, Lhx3b and actin (positive control) transcripts were detected by RT-
PCR. The Pit-1/Triple cells expressed both Lhx3a and Lhx3b, while neither transcript was 
expressed in the Pit-1/0 cells (Figure 7A). Correspondingly, LHX3 protein was detected 
in the Pit-1/Triple cells, but was not observed in the Pit-1/0 cells using western assays of 
whole cell protein extracts (Figure 7B).  
2. Identification and Investigation of Methylated Regions in Lhx3 Promoters 
 To determine if methylation might play a role in Lhx3 gene expression, 
bioinformatics was used to identify possible CpG-rich regions in the Lhx3 promoters. The 
EMBOSS CpGPlot online tool predicted a CpG-rich region encompassing the Lhx3b 
promoter of both the mouse and human genes. A CpG-rich region also was noted in the 
human LHX3a promoter, but the corresponding region in the mouse Lhx3a gene promoter 
does not have quite as high a CpG density. To further probe the role of methylation of the 
two mouse Lhx3 promoters, a 333 bp region of the mouse Lhx3a promoter (nucleotides 
-166 to +166 relative to the transcription start site) containing SP1 binding sites and 15 
CpG sites was identified for further analysis (Figure 8A). Similarly, the CpG- rich region 
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corresponding to the mouse Lhx3b promoter was covered by a 321 bp region (nucleotides 
-235 to +85) containing 30 CG sites and SP1 binding sites A (Figure 9A).  
 In order to characterize the methylation status of the Lhx3 promoters in the Pit-1/0 
cell line, genomic DNA was subjected to bisulfite conversion and sequencing. During 
bisulfite conversion, cytosines (C) are converted to thymines (T), but 5-methylcytosines 
(5mC) remain unaltered. Bisulfite sequencing from a series of individual DNA clones 
extracted from Pit-1/0 cells demonstrated that the Lhx3b promoter is highly methylated, 
while the Lhx3a promoter is less methylated (Figure 8B and 9B). Interestingly, the more 
differentiated Pit-1/Triple cells were less methylated in the central region compared to the 
precursor Pit-1/0 cells (Figure 8C and 9C).  
3. 5-Aza-2’-deoxycytidine Induces Lhx3 Gene Expression 
 To determine whether Lhx3 promoter methylation could be linked to the lack of 
detectable expression in Pit-1/0 cells, the cells were treated with the demethylating 
reagent, 5-Aza-2’-deoxycytidine (5-aza-dc). Lhx3a expression was induced 24 hours after 
2.5 μM 5-aza-dc treatment, and both transcripts were expressed 48 hours post treatment 
(Figure 10A), suggesting that methylation plays a role in Lhx3 expression. Interestingly, 
when the demethylating reagent was removed after 24 hours and the mRNA was 
harvested 48 hours after initial treatment, Lhx3 expression was repressed, consistent with 
methylation being a dynamic process (Figure 10B). Bisulfite sequencing of individual 
DNA clones from Pit-1/0 cells treated with 5-aza-dc for 48 hours (higher level of Lhx3 
transcripts) showed a decrease in methylation at specific individual sites of both the 
Lhx3a and Lhx3b promoters (Figure 11A, B). The CpG sites at +12 and +17 of the Lhx3b 
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promoter were not as affected by the treatment, with 57% and 50% of the clones 
methylated at these positions, respectively. 
4. Trichostatin A and 5-aza-dc Treatment Induce Lhx3 Expression  
 DNA methylation has been shown to recruit chromatin modifying proteins to 
modulate gene expression (reviewed in (Berger, 2002; Cosgrove and Wolberger, 2005; 
Vaissiere et al., 2008; Bogdanovic and Veenstra, 2009; Zhang and Ho, 2011; Buck-
Koehntop and Defossez, 2013)). To investigate whether the interaction between DNA 
methylation and chromatin modification could alter Lhx3 expression, Pit-1/0 cells were 
treated with both 5-aza-dc and the HDAC inhibitor, trichostatin A (TSA). The optimal 
concentration of 5-aza-dc plus TSA for Lhx3 gene expression was determined to be 2.0 
μM 5-aza-dc plus 100 nM TSA for 24 hours (Figure 12), as the 2.5 μM 5-aza-dc plus 100 
nM TSA treatment killed the cells. The combined treatment induced expression of both 
Lhx3 transcripts (Figure 13A). Bisulfite sequencing of the Pit-1/0 cells treated with 5-aza-
dc plus TSA indicated decreased methylation at specific individual sites of both Lhx3 
promoters (Figure 13B, C). Treatment with TSA plus 5-aza-dc notably decreased 
methylation at the CpG sites +12, +17, +22, +27, +38 and +52 of the Lhx3b promoter 
compared to the bisulfite sequencing of untreated Pit-1/0 cells. In dual treated cells, 
bisulfite sequencing revealed that although methylation decreased at CpG sites -206 and -
197 of the Lhx3b promoter, 50% or higher of clones still remained methylated after 
treatment. 
5. Inhibitor treatment did not induce αGSU or TSHβ gene expression 
 To determine if inhibitor treatment induced hormone gene transcription, mRNA 
was harvested from treated and untreated Pit-1/0 cells and regions of the αGSU and TSHβ 
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genes were amplified by RT-PCR. Treatment of Pit-1/0 cells with 5-aza-dc or 5-aza-dc 
plus TSA did not induce transcription of αGSU or TSHβ. Pit-1/Triple cells were used as a 
positive control for αGSU and TSHβ expression (Figure 14). 
6. The MeCP2 Methyl-Binding Protein Occupies Lhx3 Promoters 
 Methyl-CpG-binding proteins bind methylated DNA to regulate gene 
transcription (Robertson and Jones, 2000; Bogdanovic and Veenstra, 2009). MeCP2, a 
member of the methyl-binding domain (MBD) family of proteins is a regulator of global 
de novo methylation and has been shown to bind the pituitary proopiomelanocortin 
(Pomc) gene promoter (Tao et al., 2009). We determined if MeCP2 and its related protein 
family member, MBD2 were expressed in the Pit-1/0 pituitary cell line. Whole cell 
extracts from Pit-1/0 cells were subjected to Western analyses using antibodies 
recognizing MeCP2, MBD2 and GAPDH (positive control). Both MeCP2 and MBD2 
protein were detected in the Pit-1/0 cells (Figure 15A). Because treatment with the 
demethylating reagent, 5-aza-dc plus the HDAC inhibitor, TSA induced Lhx3 expression, 
we further investigated how the combined inhibitor treatment might alter the Lhx3 
promoter occupation by MeCP2 and acetylated histone 3 (acH3). Acetylation of histones 
relaxes the chromatin structure and histone acetylation is often used as a marker of gene 
activation (Berger, 2002). To examine the effects of the inhibitors, chromatin 
immunoprecipitation (ChIP) assays were performed in treated and untreated Pit-1/0 cells 
with antibodies to MeCP2, MBD2, acH3 and IgG (negative control) and primers to the 
Lhx3 promoters. The 5-aza-dc plus TSA and control plates were harvested 24 hours post 
treatment and the 5-aza-dc treated cells were harvested for chromatin 48 hours post 
treatment to capture maximized Lhx3 expression in the cells. Analysis of the ChIP assay 
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with Pit-1/0 cells treated with 5-aza-dc showed a ~five-fold decrease in acH3 occupation 
and a 1.2-fold decrease in MeCP2 occupation of the Lhx3a promoter (Figure 15B). For 
the Lhx3b promoter, 5-aza-dc treatment led to an approximately 1.5 fold increase in acH3 
occupation and no change in MeCP2 occupation compared to the respective antibody in 
untreated cells (Figure 15C). Analysis of ChIP assays with Pit-1/0 cells treated with 5-
aza-dc plus TSA indicated a ~6-fold increase in acH3 occupation and approximately a 
2.4-fold decrease in MeCP2 occupation at the Lhx3a promoter region compared to the 
respective antibody in untreated cells (Figure 15B). Occupation of acH3 at the Lhx3b 
promoter of the double treated cells increased about 20-fold, while there was no major 
change in MeCP2 occupation of the Lhx3b promoter, compared to the respective 
antibody in untreated cells (Figure 15C). MBD2 does not appear to be associated with the 
Lhx3 promoters (Figure 15B and C). A region within the Lhx3 gene was amplified as a 
negative control to show MeCP2 antibody specificity (Figure 15D).  
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Figure 7. Lhx3 mRNA and LHX3 protein are expressed in Pit-1/Triple, but not Pit-
1/0 cells. (A) Lhx3a and Lhx3b mRNA was amplified by RT-PCR in Pit-1/0 and Pit-
1/Triple cells. Beta actin primers were used in a positive control to test cDNA integrity. 
(B) Protein levels of LHX3 were determined by western blotting of whole cell protein 
extracts of Pit-1/0 and Pit-1/Triple cells, with glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as a loading control. Each experiment was performed three times with similar 
results. 
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Figure 8. Lhx3a promoter and its methylation pattern. (A) The upper diagram 
represents the mouse Lhx3 gene. Black rectangles = protein-coding exons; white areas = 
untranslated exonic regions. Two upstream promoters (aP and bP) produce the Lhx3a and 
Lhx3b mRNAs. The lower diagram methylation sites in the Lhx3a promoter (-166 to 
+166m, with the transcription start site (TSS) set to position 0). Vertical black bar = CG 
base pair; SP1 binding sites shown (Yaden et al., 2006). (B) The methylation pattern of 
the Lhx3a promoter in mouse Pit-1/0 cells and Lhx3a promoter in mouse Pit-1/Triple 
cells (C) was determined by bisulfite sequencing (methods). Black boxes = methylated 
CpGs and open boxes = non-methylated CpGs.  
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Figure 9. Lhx3b promoter and its methylation pattern. (A) The upper diagram 
represents the Lhx3b gene, with black rectangles signifying protein-coding exons and 
white areas signifying untranslated exonic regions. Two upstream promoters (aP and bP) 
produce the Lhx3a and Lhx3b mRNAs. The diagram below shows sites of methylation in 
the Lhx3b promoter (-235 to +85 with the transcription start site (TSS) set at position 0). 
Each vertical black = CG base pair. SP1 binding sites are shown. (B) The methylation 
pattern of the Lhx3b promoter in mouse Pit-1/0 cells and Lhx3b promoter in mouse Pit-
1/Triple cells (C) was determined by bisulfite sequencing (methods). Black boxes = 
methylated CpGs and open boxes = non-methylated CpGs.  
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Figure 10. Lhx3 gene expression is activated in mouse Pit-1/0 cells after treatment 
with 5’-aza-dc. (A) Pit-1/0 cells were treated with 2.5 μM 5-aza-dc and RNA was 
harvested 24 hours (left) or 48 hours (right) after treatment and RT-PCR was performed. 
(B) Lhx3 mRNA expression post removal of 5-aza-dc. Pit-1/0 cells were treated with 2.5 
μM 5-aza-dc, washed 24 hours later and mRNA was harvested 48 hours post treatment 
for RT-PCR analysis.  
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Figure 11. Bisulfite sequencing of the Lhx3 promoters post 5-aza-dc treatment. The 
methylation pattern of the Lhx3a (A) and Lhx3b (B) promoters were determined by 
bisulfite sequencing as described in the methods. Black boxes indicate methylated CpGs 
and open boxes indicate non-methylated CpGs.  
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Figure 12. Lhx3 gene expression level varies with concentration of 5-aza-dc plus 
TSA. Pit-1/0 cells were treated with varying concentrations of 5-aza-dc plus TSA and 
mRNA was harvested 24 hours post treatment for RT-PCR analysis.  
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Figure 13. Lhx3 expression is activated after treatment with 5-aza-dc plus TSA in 
Pit-1/0 cells. (A) Mouse Pit-1/0 cells were treated with 2.0 μM 5-aza-dc plus 100 nM 
TSA and harvested 24 hours after treatment for RNA. Pit-1/0 cells were treated with 2.0 
μM 5-aza-dc plus 100 nM TSA and genomic DNA was harvested for bisulfite conversion 
analysis at 24 hours post treatment. The methylation pattern of the Lhx3a (A) and Lhx3b 
(B) promoters were determined by bisulfite sequencing as described in the methods. 
Black boxes indicate methylated CpGs and open boxes indicate non-methylated CpGs.  
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Figure 14. αGSU and TSHβ hormone transcripts are not activated in treated Pit-1/0 
cells. Pit-1/0 cells were treated with 5-aza-dc or 5-aza-dc plus TSA. Hormone transcripts 
were amplified by RT-PCR (methods).  
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Figure 15. MeCP2 binds the Lhx3 gene in Pit-1/0 cells. (A) Protein levels of MeCP2 
and MBD2 were determined by western blotting, with GAPDH as a loading control. (B, 
C) ChIP assay was carried out using anti-MeCP2, anti-MBD2, anti-acetylated histone H3 
(acH3) and anti-IgG (negative control) and primers to the Lhx3a and Lhx3b promoters. 
Each experiment was performed three times with similar results. (D) ChIP assay was 
carried out using anti-MeCP2 and IgG with primers to a region of the Lhx3 gene to show 
binding specificity of anti-MeCP2 antibody.  
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Discussion 
 The anterior pituitary gland secretes hormones to regulate key physiological 
processes such as metabolism, growth, lactation, reproduction and stress response. The 
development of the hormone-secreting cell types is the result of coordinated signaling 
and interactions between key regulatory factors. One contributing transcription factor is 
the LIM-homeodomain protein, LHX3, which plays a critical role in the formation of 
somatotropes, lactotropes, gonadotropes and thyrotropes— four of the five main 
hormone-secreting anterior pituitary cell types. The functions of LHX3 in modulating 
pituitary gene expression have been extensively studied by both our lab and others; 
however, the molecular mechanisms controlling and regulating its expression are not 
fully understood. Therefore, the focus of this thesis was to determine if DNA 
methylation, a well-characterized process of gene control, contributed to the regulation of 
the Lhx3 gene.  
 DNA methylation has roles in a variety of cellular processes, including 
transcriptional regulation (Bird, 1992). Methylation occurs at the fifth position of a 
cytosine residue (5mC) in the CpG context, so GC-rich DNA regions can be modified by 
DNA methylation (Smith and Meissner, 2013). The Lhx3 gene has two TATA-less, GC-
rich promoters and recent studies have demonstrated methylated CpG islands in the 
promoters of developmental genes, such as the Hox genes (Auclair and Weber, 2012). 
Based on these findings, it was hypothesized that DNA methylation patterns may affect 
Lhx3 gene expression. This dissertation describes the first investigation of the role of 
DNA methylation in regulating Lhx3 gene transcription.  
 The recently established murine Pit-1/0 and Pit-1/Triple cell lines represent 
different phases of PIT-1- dependent cell differentiation in the mouse anterior pituitary 
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(Sizova et al., 2010). As described above, PIT-1 is a POU-homeodomain protein that is 
involved in the coordination and differentiation of somatotropes, lactotropes and 
thyrotrope cells of the anterior pituitary, and it can act synergistically with LHX3 to 
regulate pituitary genes, such as Prl (reviewed by (Savage et al., 2003)). In the Pit-1/0 
cells, the Pit-1 gene is expressed, but the cells fail to express PIT-1-dependent hormones. 
The Pit-1/Triple, representing a later phase of differentiation, express the Pit-1 gene, as 
well as the GH, PRL and TSHβ hormone genes. The expression of the Lhx3 gene in these 
“Pit-1 lineage” cell lines had yet to be determined. In this study, we found that the Pit-1/0 
cells did not express either the Lhx3 gene or the LHX3 protein, whereas the Pit-1/Triple 
cells produce LHX3. Therefore, the Pit-1/0 cells represent a valuable model to investigate 
the role of DNA methylation in Lhx3 gene expression. 
 Bioinformatics was used to identify corresponding CpG-rich regions in the mouse 
and human Lhx3 promoters for further analysis. CpG-rich regions in the Lhx3a and Lhx3b 
promoters contained two previously identified SP1 binding sites (Yaden et al., 2006). 
SP1 has established roles in basal transcriptional activity of genes with GC-rich 
promoters, and SP1 binding are known as sites of DNA methylation control in some 
cases (Li et al., 2004). Although there are multiple studies examining the methylation 
status of SP1 binding sites, the findings are conflicting. Some studies have found that 
methylation of SP1 binding sites prevents its binding and subsequent gene activation, 
while others have shown that methylation of SP1 binding sites does not alter its binding 
(e.g. (Harrington et al., 1988; Holler et al., 1988; Mancini et al., 1999; Butta et al., 2006; 
Douet et al., 2007)). We found that there was no obvious difference in methylation 
patterns associated with SP1 binding sites between the Pit-1/0 cell lines, which do not 
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express the Lhx3 gene, and the Pit-1/Triple cell line that does express the Lhx3 gene. Our 
findings suggest that the methylation status of the promoter SP1 sites is not critical for 
the transcriptional status of the Lhx3 gene.  
 To further determine how DNA methylation may impact the expression of the 
Lhx3 gene, we treated the cells with the demethylating reagent, 5-aza-dc. The reagent 
inhibits DNA methyltransferase activity, causing genome-wide hypomethylation. 
Treatment with 5-aza-dc induced expression of both Lhx3 mRNA transcripts in the Pit-
1/0 cells, with increased expression correlating with longer exposure to the reagent. 
These results are similar to various other studies that have used 5-aza-dc to induce gene 
expression (Bovenzi and Momparler, 2001; Glait-Santar and Benayahu, 2011; Hansberg-
Pastor et al., 2013). A series of DNA clones from treated cells was subjected to bisulfite 
sequencing, and results showed a decrease in methylation at both the Lhx3a and the 
Lhx3b promoter CpG regions. Together, this data suggest that methylation may be part of 
Lhx3 gene inactivity in Pit-1/0 cells.  
 The methylation process was further examined by removing the demethylating 
reagent and then assaying for Lhx3 gene expression 24 hours post removal. Removal of 
the 5-aza-dc demethylating reagent led to silencing of the Lhx3 gene within 24 hours. The 
mechanism of 5-aza-dc and its analog 5-azacytidine in blocking methylation have been 
studied in cultured cells (Creusot et al., 1982; Taylor and Jones, 1982; Christman et al., 
1983). DNA methyltransferases irreversibly interact with 5-aza-dc and its analogs, 
forming adducts that if not repaired, become mutagenic and cytotoxic (Creusot et al., 
1982; Taylor and Jones, 1982; Christman et al., 1983; Jackson-Grusby et al., 1997). 
Additionally, it has been found that DNMT1 becomes deactivated after azacytidine is 
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incorporated into the DNA, resulting in passive loss of DNA methylation a few hours 
after treatment (Creusot et al., 1982). A similar mechanism may be occurring in the Pit-
1/0 cells, in which DNMT1 binds to a target hemi-methylated DNA template strand and 
irreversibly binds the incorporated 5-aza-dc on the nascent strand to form an adduct that 
prevents DNA methylation. Because the cells are treated with a low dose of 5-aza-dc, 
there may be a population of methylated and unmethylated DNA in the cell, which would 
explain the amplification of the Lhx3 gene. Removal of the 5-aza-dc may give the cell 
time to repair the adducts, prevent new adducts from forming and properly replicate the 
existing methylated DNA. The population of unmethylated DNA may not be high enough 
for amplification by PCR.  
 Acetylation is a well characterized post-translational histone modification that is 
often a marker of gene activation (reviewed in (Berger, 2002)). The addition of an acetyl 
group is catalyzed by histone acetyl transferases (HATs), whereas the removal of acetyl 
groups is catalyzed by histone deacetylases (HDACs). Furthermore, it has been shown 
that silenced genes can be re-activated by treatment with 5-aza-dc plus TSA (Cameron et 
al., 1999). Interestingly, treatment of Pit-1/0 cells with both 5-aza-dc and the HDAC 
inhibitor, TSA led to induction of both Lhx3 mRNA transcripts, suggesting possible 
cross-talk between the DNA methylation and chromatin microenvironment. Similar 
results have been seen in other studies, involving 5-aza-dc and TSA treatment to induce 
gene activity. For example, 5-aza-dc weakly activated expression of the retinoic acid 
reporter and estrogen receptor α genes in MDA-MB-231 breast cancer carcinoma cells, 
while the combination treatment of 5-aza-dc plus TSA resulted in greater activation of 
both genes (Bovenzi and Momparler, 2001). 
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 Methyl-CpG binding proteins recruit histone modifiers to modulate transcription, 
so communication between methyl-CpG binding proteins and chromatin modifiers may 
influence Lhx3 mRNA expression. The methyl-binding protein, MeCP2 has been shown 
to bind the pituitary Pomc gene promoter (Tao et al., 2009), and we therefore 
hypothesized that MeCP2 may be similarly associated with the methylated Lhx3 
promoters. ChIP assay analysis indicated that the MeCP2 is associated with both Lhx3 
promoters in Pit-1/0 cells. MeCP2 has recently been shown to interact with AT-rich 
DNA, through AT-hook domains (Baker et al., 2013). The Lhx3 pituitary enhancer, Core 
R3 is AT-rich, so it may be possible that MeCP2 mediates the interaction between the 
Lhx3 promoter and its enhancer. In this model, MeCP2 would serve as a co-activator of 
the Lhx3 gene, with its function potentially determined by both cis- and trans-regulatory 
elements.  
 The C-terminal transcriptional repression domain (TRD) of MeCP2 has been 
shown to recruit histone deacetylases to modulate gene expression (Jones et al., 1998; 
Nan et al., 1998). Therefore, we performed ChIP assays to investigate whether inhibiting 
HDACs and/or blocking methylation would alter MeCP2 and acetylated histone H3 
(acH3) occupation of the Lhx3 promoters. Interestingly, the treatments resulted in 
different effects on each Lhx3 promoter. Analysis of the ChIP assay with Pit-1/0 cells 
treated with 5-aza-dc showed a decrease in both acH3 occupation and MeCP2 occupation 
of the Lhx3a promoter. The decrease is MeCP2 occupation is expected, since the reagent 
blocks methylation and thereby potentially prevents MeCP2 from binding the methylated 
DNA. The decrease in acH3 occupation of the Lhx3a promoter with 5-aza-dc treatment 
suggests potential cross-talk between chromatin status and DNA methylation. One 
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possible explanation for the decrease is acH3 occupation of the promoter is that MeCP2 
also interacts with chromatin modifying proteins to activate genes (Jones et al., 1998; 
Nan et al., 1998; Lunyak et al., 2002; Chen et al., 2013). For example, a study showed 
that MeCP2 recruits CREB1 to activate the murine neuronal glucose transporter isoform 
3 (Glut3) gene in murine neurons (Chen et al., 2013). Therefore, blocking methylation 
with 5-aza-dc prevented MeCP2 from binding and recruiting other proteins that could 
potentially increase or maintain basal histone acetylation at the promoter. 
 At the Lhx3b promoter, 5-aza-dc treatment led to an increase in acH3 occupation 
and no change in MeCP2 occupation compared to untreated cells. Because MeCP2 
recruits HDACs, blocking methylation may prevent binding of MeCP2 to methylated 
DNA and subsequent recruitment of HDACs to histones. The absence of recruited 
HDACs to histones may translate to a decrease is histone deacetylation and possibly an 
increase in acetylation of histone H3. The lack of change in Lhx3b promoter occupation 
by MeCP2 may be due to the fact that some sites still remain methylated in the Lhx3b 
promoter after treatment and therefore may facilitate the binding of MeCP2 to the 
promoter. Additionally, the resolution of the ChIP assay is limited by sonication of DNA 
fragments less than 1 kb, so determining precise resolution of changes in MeCP2 
occupation may be challenging; nonetheless, the examined sequence is within a key 
regulatory region of the Lhx3 gene.  
 Unlike ChIP assays performed with the 5-aza-dc treatment, analysis of ChIP 
assays performed with Pit-1/0 cells treated with 5-aza-dc plus TSA indicated an increase 
in acH3 occupation and a decrease in MeCP2 occupation at the Lhx3a promoter region 
compared to the respective antibody in untreated cells. These results suggest cross-talk 
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and possible synergy between methyl-binding proteins and chromatin modifying proteins 
in regulating gene transcription, which has been seen in other studies (Jones et al., 1998; 
Nan et al., 1998; Klose and Bird, 2004). An increase in occupation of acH3 at the Lhx3b 
promoter resulted from the 5-aza-dc plus TSA treatment, while there was no major 
change in MeCP2 occupation of the Lhx3b promoter, compared to untreated cells. Again, 
the lack of change in MeCP2 occupation may be due to the remaining methylated sites 
after treatment. 
 Transcription is a dynamic process. Modifying epigenetic marks of the genes in a 
cell by treatment with HDAC inhibitors and/or demethylating reagents may alter the 
temporal expression of some genes, which in turn may result in downstream changes to 
both coordinated protein-protein interactions and protein-DNA interactions. Therefore, 
expression of the Lhx3 gene induced by treatment with the HDAC inhibitor and/or the 
demethylating reagent is most likely the result of both direct and indirect effects. The 
change in methylation patterns after treatment (demonstrated by the Lhx3 bisulfite 
sequencing) and the subsequent induction of the Lhx3 gene suggest a direct effect, but it 
should be noted that other untested regions of the gene probably contributed to its 
expression, as well. Furthermore, the transcription of other genes that regulate Lhx3 may 
have been altered by the inhibitor treatment, contributing to the indirect induction of the 
Lhx3 gene. Interestingly, treatment of Pit-1/0 cells with 5-aza-dc and 5-aza-dc plus TSA 
did not lead to induction of the αGSU or TSHβ genes, which are downstream LHX3 and 
PIT-1 target genes. Additional actions therefore are required to achieve a differentiated 
derivative of Pit-1/0 cells that express these hormone components. While this observation 
indicates gene expression specificity after the cell treatments (i.e. it demonstrates that the 
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treatments do not generically activate many other pituitary-expressed genes in addition to 
Lhx3), the lack of hormone transcript expression may also be the result of indirect effects. 
For example, treating the Pit-1/0 cells with inhibitors may have induced expression of a 
αGSU or TSHβ repressor gene. It should also be mentioned that LHX3 protein levels in 
treated cells were not assayed, so it is possible that the Lhx3 transcripts were not 
translated and therefore there is not LHX3 protein to interact with partners such as PIT-1 
to induce the expression of hormone genes such as αGSU or TSHβ. 
 Collectively, these findings implicate DNA methylation in the regulation of 
mouse Lhx3 gene transcription. We have shown that the demethylating reagent, 5-aza-dc 
can induce Lhx3 gene activation both independently, and in combination with the HDAC 
inhibitor, TSA, in a pituitary precursor cell, suggesting crosstalk between DNA 
methylation and chromatin modifiers. The methyl-binding protein, MeCP2 has been 
shown to occupy the Lhx3 promoter in Pit-1/0 cells and it may function as either a 
transcriptional repressor or activator, depending on the specific chromatin architecture or 
cellular environment. 
 Further studies still need to be performed to fully understand the role of DNA 
methylation in Lhx3 gene regulation. This study only examined the activation of Lhx3 in 
the murine pituitary Pit-1/0 cells, so similar studies could be performed in other pituitary 
cell lines that do not express the Lhx3 gene, such as pituitary pre-somatotrope cell line 
GHFT1 (Sloop et al., 2001). Higher concentrations of 5-aza-dc should also be tested to 
see if both Lhx3 gene transcripts could be expressed after 24 hours post treatment. Other 
GC-rich promoter regions should also be examined for occupation by both MeCP2 and 
other methyl-CpG binding proteins. It would be interesting to see if higher doses of 5-
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aza-dc plus TSA eventually led to reactivation of the Lhx3 gene and its downstream 
pituitary gene targets. Also, one could study if DNMT1 is the methyltransferase 
regulating the Lhx3 gene expression in the Pit-1/0 cells by using DNMT1 inhibitors, such 
as DNMT1 small interfering RNA (siRNA).  
 Other studies could be designed to further explore the interactions between 
HDACs, MeCP2 and the Lhx3 promoters. As mentioned earlier, MeCP2 binds AT-rich 
DNA sequences and the Lhx3 enhancer is AT-rich. Therefore, a further study using 
Combined 3C-ChIP-Cloning (6C) technology could test whether or not MeCP2 
modulates this interaction. Co-immunoprecipitation assays could be performed to 
confirm interaction of MeCP2 with HDACs in Pit-1/0 cells, and sequential chromatin 
immunoprecipitation assays (also known as re-chip assays) could be performed to 
determine if HDAC and MeCP2 proteins simultaneously bind the same region of the 
Lhx3 promoter. Additionally, ChIP assays could also be performed to examine the 
occupation of the Lhx3 promoters by other histone markers, such as methylation at lysine 
9 of histone H3, as MeCP2 has also been shown to recruit histone methyltransferases to 
this site (Lunyak et al., 2002; Fuks et al., 2003). 5mc can be oxidized to form 5-
hydroxymethyl-cytosine (5hmC), which is up regulated in neuronal tissues (Kriaucionis 
and Heintz, 2009; Tahiliani et al., 2009; Nestor et al., 2012) and the conversion can be 
detected by chromatography coupled to mass spectroscopy or 5hmC DNA 
immunoprecipitation. Mellén and colleagues recently showed that MeCP2 binds 5hmC in 
neuronal tissues (Mellen et al., 2012). Lhx3 mRNA has been detected in ventral spinal 
cord, the pons, the medulla oblongata and the pineal gland, so further analysis of the gene 
should be conducted to determine if it contains the 5hmC modification and if MeCP2 
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binds the 5hmC modified DNA in these tissues (Seidah et al., 1994; Zhadanov et al., 
1995).  
 LHX3 plays a critical role in pituitary development, and mutations in human 
LHX3 lead to combined pituitary hormone deficiency disease (CPHD). Therefore, 
discovering cellular processes that potentially influence LHX3/Lhx3 expression, such as 
DNA methylation contribute to our understanding of pituitary organogenesis. 
Additionally, this study identifies potential candidate regions of the Lhx3 gene that may 
be used in the diagnosis of CPHD patients of unknown etiology.  
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